ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1782

A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model

Lin-Yu Geng1, Ivan Molano 2, Ling-Xiao Xu 3, Qing Sun 1, Phillip Ruiz 4, Quan-Zhen Li 5, Gary Gilkeson 6 and Betty Tsao 7, 1Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, 2Division of Rheumatology & Immunology/Medical University of South Carolina, Charelston, 3Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charelston, SC, 4Department of Surgery/University of Miami School of Medicine, Charleston, 5Department of Immunology & Internal Medicine/University of Texas Southwestern Medical Center, Charleston, 6Division of Rheumatology & Immunology/Ralph H. Johnson VA Medical Center/Medical University of South Carolina, Charleston, SC, 7Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Follicular Helper T cell and Reactive oxygen species, Ncf1-R90H variant, pristane induced C57BL/6 mouse model, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M094: SLE – Animal Models (1782–1787)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: We previously identify a p.Arg90His (p.R90H) substitution encoded in phagocyte neutrophil cytosolic factor (NCF1) as a novel risk variant for SLE, with decreased and increasedNCF1copy numbers predisposing to and protecting against SLE, respectively. Our data highlights the pathogenic role of reduced reactive oxygen species (ROS) production in SLE. To study how reduced ROS promotes lupus, we established a C57BL/6 (B6) mouse model with a knock-in (KI) 90H mutation in Ncf1locus by CRISPR/Cas9 genome editing.

Methods: We compared 90H KI and wild-type (WT) R90 littermates for R90H genotypic effects on ROS production, type I interferon (IFN-I) signature and immune cell subsets in splenocytes, autoantibody production by ELISA and slide-based antigen array, renal IgG and C3 deposition and pathology. Pristane was injected intraperitoneally twice as an environmental trigger (0.1ml at 8wks and 0.5ml at 10wks), and lupus-like features were assessed at 30-36 wks.

Results: Compared with R90 WT littermates,untreated 5-week-old 90H KI mice exhibited reduced phorbol myristate acetate-induced extracellular ROS in splenocytes (n=5, p=0.03), splenomegaly (n=5, p=0.02),elevated IFN-I scores (p=0.047), as well as increased numbers of CD4+CXCR5++PD-1++follicular helper T cells (Tfh, p=0.045) and CD19+CD23highCD21intfollicular B cells (p=0.005). Because KI mice had no spontaneous kidney disease at one-year old, we used pristane injection to induce lupus. Compared with pristane-treated female WT mice (n=10), 30-36-week-old female KI littermates (n=8) developed lupus-like manifestations including splenomegaly (p=0.02), increased IgG anti-RNP (p=0.02) and total IgG (p=0.004) levels, glomerulonephritis with increased glomerular score (p=0.046), elevated renal deposition of IgG (p=0.005) and C3 (p=0.04). IgG autoantibody profiles confirmed elevated IgG anti-Sm, dsDNA and RNP in those female KI mice. Increased numbers of B220+IgDlowCD95highGL7highgerminal center B cells (p=0.03) and CD4+CXCR5++PD-1++(p=0.04) or CD4+Bcl-6+(p=0.02) Tfh were found in 30-36-week-old pristane-treated KI mice.

Conclusion: A single nucleotide polymorphism p.Arg90His (p.R90H) in the Ncf1gene resulted in reduced oxidative burst, elevated IFN-I scores, splenomegaly, and increased cell numbers of Tfh and follicular B cells in 5-week-old 90H KI C57BL/6 mice. Pristane treatment caused increased IgG autoantibodies and kidney disease development in 30-36-week-old female 90H KI C57BL/6 mice. The disease development might be attributed to increased cell numbers of Tfh, facilitating germinal center formation and autoantibody production.


Disclosure: L. Geng, None; I. Molano, None; L. Xu, None; Q. Sun, None; P. Ruiz, None; Q. Li, None; G. Gilkeson, None; B. Tsao, None.

To cite this abstract in AMA style:

Geng L, Molano I, Xu L, Sun Q, Ruiz P, Li Q, Gilkeson G, Tsao B. A Human SLE Variant NCF1-R90H Drives Lupus-like Kidney Disease in a Pristane-induced Murine Lupus Model [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-human-sle-variant-ncf1-r90h-drives-lupus-like-kidney-disease-in-a-pristane-induced-murine-lupus-model/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-human-sle-variant-ncf1-r90h-drives-lupus-like-kidney-disease-in-a-pristane-induced-murine-lupus-model/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology